Elena A. Pronina

Elena A. Pronina

Auto-generated profile, based on publicly available information

Elena A. Pronina

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk, Russian Federation; Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care named after N.S. Karpovich; Krasnoyarsk, Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Siberian Medical Review
Verified
Journal Article
Closed access
PUProf. V. F. Voino-Yasenetsky Krasnoyarsk State Medical University
Prof. V. F. Voino-Yasenetsky Krasnoyarsk State Medical University
MPMarina Petrova
Marina Petrova
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
VIV.M. Bekhterev Psychoneurological Research Institute
V.M. Bekhterev Psychoneurological Research Institute
EPE.A. Pronina
E.A. Pronina
OBOlga Bobrova
Olga Bobrova

10 October 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ORO Rotar
O Rotar
EME Moguchaya
E Moguchaya
MBM Boyarinova
M Boyarinova
OROlesya Rubanenko
Olesya Rubanenko
EGE Gubareva
E Gubareva
ESE Shlyakhto
E Shlyakhto
Aim. To evaluate the features of antihypertensive therapy (AHT), adherence to therapy and achievement of target blood pressure (BP) in patients with hypertension (HTN) in Russian real-world practice after the implementation of 2024 Russian clinical guidelines on hypertension in adults.Material and methods. During May 2025, 7990 patients with HTN from 19 Russian cities and Tiraspol (Pridnestrovian Moldavian Republic) took part in the BP measurement campaign. Outpatients with HTN over the age of 18 voluntarily participated in the campaign. During the screening, BP and pulse were measured three times using an automatic or mechanical BP monitor. In addition, a questionnaire was filled out on behavioral risk factors, BP self-monitoring skills, medication adherence, AHT, comorbidities and related therapy. The effectiveness of AHT was understood as achieving the target BP level <140/90 mm Hg in patients with HTN and taking AHT, and BP control — in all hypertensive patients, regardless of taking AHT.Results. The analysis included 7972 respondents aged 18 to 96 years (median age 62 years [51;71]), including 3372 men (42,3%). Among the participants, 74,4% took AHT, while 62,6% achieved target BP <140/90 mm Hg and 25,8% — target BP <130/80 mm Hg. On-demand therapy remains the leading reason for not taking AHT among patients with HTN. Approximately half of the participants (57,7%) answered that they do not use medication reminder systems. Most often, hypertensive patients use BP self-monitoring diaries and pill boxes. Every fifth patient with HTN was registered as taking antihypertensive monotherapy, every third as dual AHT, and every fourth as triple AHT. Single-pill combinations were taken by 34,5% of patients. In outpatient practice, following sex differences were revealed: significantly higher prevalence of taking AHT, using AHT reminder systems, discussions with a doctor, and the effectiveness of treatment and control of HTN were characteristic of female patients. Discussion with a doctor about the importance of following recommendations was associated with a significantly higher achievement of target BP level (odds ratio (OR) 1,43), the use of a single-pill AHT combination (OR 1,3) and statin therapy (OR 1,39), p<0,0001.Conclusion. In outpatient practice after the implementation of 2024 Russian clinical guidelines for HTN, an increase in the coverage and efficacy of AHT, and the HTN control is observed compared to the population data of 2020-2022. AHT prescription profile indicates a decrease in the share of monotherapy and an increase in the share of triple combination. The use of single-pill antihypertensive combinations is growing, but remains insufficient. The results obtained demonstrate the importance of discussing with a physician the need to comply with recommendations in hypertensive patients to improve adherence and treatment effectiveness.

1 January 2026 in Doctor.Ru
Verified
Journal Article
Open access
EHE.I. Harkov
E.I. Harkov
NTN.YU. Tsibulskaya
N.YU. Tsibulskaya
EPE.A. Pronina
E.A. Pronina
MPMarina Petrova
Marina Petrova
EKE.M. Karih
E.M. Karih
Aim. To demonstrate, using a clinical case, the impact of a large number of cardiometabolic risk factors on the development of cardiovascular diseases in Shereshevsky — Turner syndrome. Key points. The prevalence of cardiovascular diseases and cardiovascular mortality in adult women with Shereshevsky — Turner syndrome is significantly higher than in the general population. In the presented clinical case, a patient with mosaic Shereshevsky — Turner syndrome, despite long-term hormone replacement therapy, developed a silent myocardial infarction, to which such cardiometabolic risk factors as smoking, arterial hypertension, hypothyroidism, and poor control of type 1 diabetes mellitus contributed. The specific features of the myocardial infarction course in this patient also include a discrepancy between the area of myocardial damage according to echocardiography and the diameter of the infarct-related coronary artery. Conclusion. Women with Shereshevsky — Turner syndrome require continuous, multifactorial lifelong monitoring for the prevention, early detection, and treatment of cardiovascular diseases. Keywords: Shereshevsky — Turner syndrome, acute myocardial infarction, cardiometabolic factors

30 December 2023 in Russian Journal of Education and Psychology
Verified
Journal Article
Open access
PDF file
EPElena A. Pronina
Elena A. Pronina
NSNatalya Shimokhina
Natalya Shimokhina
DKDarya S. Kaskaeva
Darya S. Kaskaeva
LDLyudmila K. Danilova
Lyudmila K. Danilova
OTOlga V. Tutinina
Olga V. Tutinina
MPMarina Petrova
Marina Petrova
Background. Anxiety is more common in patients with hypertension. The comorbid presence anxiety disorders and arterial hypertension complicates medical treatment, may change the severity and/or progression of disease. Objective. To study the influence of comorbid diseases on the development of anxiety disorders in patients with hypertension in outpatient practice. Methods. This observational cohort study employed the State‐Trait Anxiety Inventory (STAI, Spielberger anxiety scale) to assess symptoms of anxiety in several groups with hypertension. The study cohort included 360 patients with isolated hypertension, 172 patients with hypertension in combination with obesity and 72 patients with comorbid hypertension and type 2 diabetes mellitus (DM) Results. A high incidence of anxiety disorders was found in patients with hypertension 98.06% regardless of the presence of obesity 97.09% and type 2 diabetes 98.18%. The incidence and severity of trait anxiety in the examined patients was the lowest in the group of patients with hypertension in combination with obesity 59.65%, compared with patients with isolated hypertension 68.61% p =0.042045 and the group of hypertension in combination with type 2 diabetes 78.18% p=0.012662. According to the severity of the combination of hypertension with obesity, patients with a low 40.35% and an average 41.52% indicator of trait anxiety prevailed, in patients with hypertension in combination with type 2 diabetes, an average 52.73% and a high 25.45% level of anxiety were more often observed (p<0.5). The presence of type 2 diabetes increases the frequency and severity of state anxiety in patients with hypertension. Thus, patients with hypertension in combination with type 2 diabetes were more likely to have a high (50.91%) level of state anxiety, while patients with isolated hypertension were more likely to have low (5.56%) and medium (70.35%) levels of anxiety disorders.

22 June 2025 in Yakut Medical Journal
Verified
Journal Article
Open access
PDF file
SSS. Yu. Shtarik
S. Yu. Shtarik
SBS. S. Bogomolova
S. S. Bogomolova
MPMarina Petrova
Marina Petrova
LDL. K. Danilova
L. K. Danilova
EZE. V. Zorina
E. V. Zorina
EPE. A. Pronina
E. A. Pronina
The scientific review examines chronic kidney disease (CKD) in combination with chronic non-communicable diseases. Chronic kidney disease is a serious and growing public health problem worldwide, characterized by a gradual and irreversible decline in kidney function and is one of the leading causes of death worldwide. The priority task of healthcare is the prevention of chronic non-communicable diseases, among which the most significant include cardiovascular diseases, bronchopulmonary diseases, diabetes mellitus, and oncological diseases. The association of CKD with chronic non-communicable diseases, in particular with cardiovascular diseases, makes this pathology especially dangerous, which leads to a deterioration in the quality of life of patients and an increase in mortality. The treatment of patients with comorbid pathology requires a comprehensive and interdisciplinary approach.